- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Metronidazole reasonable treatment option for patients with symptomatic oral lichen planus
USA: A recent study published in Clinical and Experimental Dermatology has shown metronidazole to be a reasonable option for patients with symptomatic oral lichen planus (OLP) who have failed topical treatment options.
The researchers suggested metronidazole to be a reasonable option given its efficacy, mild side effect profile, and less immunosuppressive nature as compared to alternative systemic treatment options.
At least partial response was seen in 60.0% of the patients treated with metronidazole 500 mg twice daily, with complete response noted in 33.3% of the patients.
Lichen planus is an inflammatory dermatosis with mucosal variants, including oral lichen planus. OLP has relapsing chronic courses and may have a significant impact on quality of life. Following approval from the FDA's Institutional Review Board (IRB), Alison N Hollis, University of North Carolina at Chapel Hill, North Carolina, USA, and colleagues analyzed metronidazole's efficacy as a treatment for oral lichen planus by retrospective chart review of patients at the institution over 10 years with a diagnosis of OLP. The study included patients with concomitant use of topical treatments.
Thirty patients with oral lichen planus were treated with metronidazole 500 mg twice daily. Most patients (n=18, 60.0%) showed improvement with metronidazole, including 10 (33.3%) with complete resolution of symptoms.
The results are limited by the nature of a retrospective review study with a relatively small cohort treated with metronidazole.
Despite multiple limitations of the study, the researchers conclude, "oral metronidazole may be a relatively well-tolerated treatment option for patients with OLP who have failed treatment with first-line topical corticosteroids."
"Given the mild side effect profile, efficacy, and the less immunosuppressive nature of metronidazole compared to alternative systemic treatment options, metronidazole is a reasonable option to try in patients with symptomatic oral lichen planus who have failed topical treatment options," they wrote.
Reference:
Hollis, A. N., Myers, E. L., & Culton, D. A. A retrospective cohort study on the efficacy of metronidazole in oral lichen planus. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad268
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751